• J Formos Med Assoc · Dec 2024

    Colchicine to prevent cardiovascular death after an acute myocardial infarction.

    • Yu-Ching Chang, Lo-Chia Yeh, Ting-Tse Lin, Ching-Chang Huang, Chi-Sheng Hung, Yen-Yun Yang, Shu-Lin Chuang, Lian-Yu Lin, Lung-Chun Lin, Hsien-Li Kao, and Yen-Hung Lin.
    • Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
    • J Formos Med Assoc. 2024 Dec 2.

    BackgroundClinical and experimental evidence have demonstrated the protective benefits of colchicine in acute myocardial infarction (AMI) through its potential anti-inflammatory effect. However, investigations on the Asian population are limited.MethodsThis retrospective longitudinal cohort study used electronic medical records from a tertiary medical center in Taiwan. Patients with their first AMI from the emergency department between 2010 and 2020 were included. The outcomes included all-cause death, hospitalization for heart failure, stroke, and emergency admission for angina. Propensity-score matching (PSM, 5 to 1) and Cox's proportional hazards regression model were used to estimate hazard ratios (HRs).ResultsA total of 2841 patients with their first admission for AMI were identified, of which 176 (6.2%) received colchicine and 2665 (93.8%) did not. After a median follow-up of 21.4 months, the incidence of all-cause death was significantly reduced in the colchicine group (HR, 0.560; 95% confidence interval [CI], 0.361-0.862; P = 0.008), driven by the significant risk reduction of cardiovascular death (HR, 0.291; 95% CI, 0.142-0.613; P = 0.001). There was no significant difference of other outcomes. After PSM, the protective effect remained in the colchicine group compared with non-users (HR, 0.331; 95% CI, 0.162-0.690; P = 0.003). The relationship between endpoints and various time-to-treatment initiation showed a significant reduction in the risk of all-cause death for whom colchicine was initiated < Day 3 compared with placebo.ConclusionsLow-dose colchicine led to a significantly lower risk of cardiovascular death than non-users among patients with a recent myocardial infarction. They benefit from early, in-hospital initiation of colchicine after AMI.Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.